Figitumumab Combined With Pegvisomant For Advanced Solid Tumors

Stopped early · Phase 1

Conditions studied: Colorectal Neoplasms, Lung Neoplasms, Breast Neoplasms, Prostatic Neoplasms, Sarcoma

In brief

This is a Phase 1 study investigating the safety and tolerability of Figitumumab plus Pegvisomant for treatment of advanced solid tumors.

Key facts

Study ID

NCT00976508

Run by

Pfizer

People needed

24

Starts

2009-11-01

Expected to finish

2012-10-01

Last updated by the study team

2013-12-13

Who can join

Age: 10 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients ≥18 years of age with advanced solid tumors for which the combination of figitumumab and pegvisomant are reasonable treatment options.
• Patients between the ages of 10 and 18 years with advanced sarcomas for which there is no available curative therapy or therapy proven to prolong survival with an acceptable quality of life will be included in the Sarcoma Expansion Cohort.
• Adequate recovery from prior therapies.
• Adequate organ function (i.e. bone marrow, kidney, liver)
• Total IGF-1 ≥100 ng/ml (13 nmol/L).

You may not qualify if…

• Concurrent treatment with any anti-tumor agents.
• Pregnant or breastfeeding females.
• Significant past history or active cardiac disease
• Active infection
• History of diabetes mellitus.
• Glycosylated hemoglobin >5.7

Where it is running

• Pfizer Investigational Site — Minneapolis, Minnesota, United States
• Pfizer Investigational Site — Rochester, Minnesota, United States
• Pfizer Investigational Site — Montreal, Quebec, Canada
• Pfizer Investigational Site — Helsinki, Finland
• Pfizer Investigational Site — Münster, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.